AbbVie Inc. logo

AbbVie Inc. (ABBV)

Market Closed
27 Feb, 20:00
NYSE NYSE
$
232. 03
+7.34
+3.27%
$
397.32B Market Cap
42.2 P/E Ratio
1.63% Div Yield
4,213,578 Volume
10.28 Eps
$ 224.69
Previous Close
Day Range
225.1 232.19
Year Range
164.39 244.81
Want to track ABBV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
ABBV earnings report is expected in 54 days (23 Apr 2026)
Dividend Income Summary: Lanny's August 2024 Summary

Dividend Income Summary: Lanny's August 2024 Summary

Investing in dividend stocks allows you to earn dividend income, the best passive income stream. In August, we (my wife and I) received a dividend income total of $1,415.47. 2023 was up 24%. Eight months down in 2024 and the S&P 500 is still up 14%, despite the recent sell-offs. Unemployment is starting to tick up recently.

Seekingalpha | 1 year ago
Why AbbVie (ABBV) Outpaced the Stock Market Today

Why AbbVie (ABBV) Outpaced the Stock Market Today

AbbVie (ABBV) closed the most recent trading day at $196.42, moving +1.56% from the previous trading session.

Zacks | 1 year ago
3 Things You Need to Know if You Buy AbbVie Stock Today

3 Things You Need to Know if You Buy AbbVie Stock Today

AbbVie's leadership and revenue mix have changed, and more change is coming. There's a good chance that it will diversify into a new pharmaceutical segment.

Fool | 1 year ago
3 No-Brainer Dividend Stocks to Buy in September

3 No-Brainer Dividend Stocks to Buy in September

AbbVie is a Dividend King with solid growth prospects. Merck's looming patent cliff isn't as alarming as it might seem.

Fool | 1 year ago
Got $1,000? 3 Healthcare Stocks to Buy and Hold Forever

Got $1,000? 3 Healthcare Stocks to Buy and Hold Forever

Hims & Hers is rapidly picking up steam in the telehealth industry. UnitedHealth's dominance has created massive wealth for long-term investors.

Fool | 1 year ago
AbbVie Stock Up Almost 20% in 3 Months: Buy, Sell or Hold?

AbbVie Stock Up Almost 20% in 3 Months: Buy, Sell or Hold?

Investors who own ABBV stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff, quite well and looks set to return to robust growth next year.

Zacks | 1 year ago
AbbVie Stock Post Humira is Still an Attractive Stock to Hold

AbbVie Stock Post Humira is Still an Attractive Stock to Hold

AbbVie NYSE: ABBV is a global biopharmaceutical company long synonymous with its blockbuster drug, Humira. While the drug's success has propelled AbbVie to great heights, its recent patent expiration has greatly influenced the company's future.

Marketbeat | 1 year ago
What's Behind The 2x Jump In AbbVie Stock?

What's Behind The 2x Jump In AbbVie Stock?

AbbVie stock (NYSE: ABBV) has more than doubled in value since early January 2021 - jumping from levels of $90 then to around $195 now - vs. an increase of about 50% for the S&P 500 over this period.

Forbes | 1 year ago
2 Dividend Stocks You Can Safely Hold Through a Recession

2 Dividend Stocks You Can Safely Hold Through a Recession

These two companies sell products that remain in high demand even during recessions. They also have excellent dividend track records -- and one of them is a Dividend King.

Fool | 1 year ago
2 High-Yield Dividend Stocks to Buy in September and Hold for a Decade or Longer

2 High-Yield Dividend Stocks to Buy in September and Hold for a Decade or Longer

Historically, September is a relatively bad month for stock markets. AT&T offers a huge dividend yield and it could start raising the payout again next year.

Fool | 1 year ago
2 Monster Stocks You Can Buy Right Now Before They Surge Even Higher

2 Monster Stocks You Can Buy Right Now Before They Surge Even Higher

Consumers are still spending money on healthcare and fast-casual dining. AbbVie is a faithful dividend payer with a blockbuster portfolio.

Fool | 1 year ago
3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever

3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever

Abbott Labs produces medications as just one of its revenue sources. AbbVie has shown a knack for expanding the markets of its drugs.

Fool | 1 year ago
Loading...
Load More